- Hims & Hers will offer FDA-approved Ozempic and Wegovy at self-pay prices starting later this month.
- Wegovy pill showed 17% weight loss in OASIS 4 trial with diet and exercise.
- Novo Nordisk dismisses patent lawsuit against Hims & Hers but reserves the right to refile.
Agreement Details
Novo Nordisk has partnered with telehealth company Hims & Hers to provide access to FDA-approved semaglutide medicines, including Ozempic and Wegovy, at self-pay prices. This agreement will take effect later this month, allowing Hims & Hers customers to access these medications at the same prices as other telehealth platforms.
Shift in Business Model
Hims & Hers will transition its GLP-1 business model to focus on FDA-approved medicines, ceasing the advertisement of compounded GLP-1 offerings. Existing patients will have the option to switch to FDA-approved alternatives in consultation with healthcare professionals.
Clinical Trial Results
In the OASIS 4 trial, the Wegovy pill demonstrated an average weight loss of 17% when combined with a reduced-calorie diet and exercise, compared to 3% for placebo. Common adverse reactions included nausea, diarrhea, and vomiting, similar to those seen in previous trials with Wegovy injection.
Legal Implications
As part of the agreement, Novo Nordisk is dismissing its patent infringement lawsuit against Hims & Hers but reserves the right to refile in the future.
